目的:探究行胰腺癌根治手术患者放化疗对患者预后的影响。方法:选取SEER数据库中2010年到2015年行根治手术治疗的胰腺癌患者,采用COX比例风险模型、χ2和Kaplan-Meier法,进行分析。结果:年龄是影响胰腺癌患者术后的独立影响因素,中青年患者预后较老年患者好,但无论在老年组还是中青组,对于临床分期和TNM分期较差的患者,放疗和化疗可以改善患者的预后。但对分化程度、临床分期和TNM分期较好的患者,化疗和放疗可能不利于其预后。结论:对于临床分期和TNM分期差的行根治手术患者,放疗和化疗能显著改善其预后,使其生存周期延长。
Objective: To investigate the effect of radiotherapy and chemotherapy on prognosis of patients un-dergoing radical surgery for pancreatic cancer. Methods: Patients with pancreatic cancer who un-derwent radical surgery from 2010 to 2015 were selected from the SEER database and analyzed by COX proportional risk model, χ2 and Kaplan-Meier. Result: Age is an independent factor affecting postoperative pancreatic cancer patients, and the prognosis of young and middle-aged patients is better than elderly patients, but whether in the elderly group or the middle-aged group, radio-therapy and chemotherapy can improve the prognosis of patients with poor clinical stage and TNM stage. However, chemotherapy and radiotherapy may be detrimental to the prognosis of patients with better differentiation, clinical stage and TNM stage. Conclusion: For patients with poor clinical stage and TNM stage, radiotherapy and chemotherapy can significantly improve their prognosis and prolong their survival cycle.
胰腺癌,根治手术,预后,放化疗, Pancreatic Cancer Radical Surgery Prognosis Radiotherapy and Chemotherapy摘要
Objective: To investigate the effect of radiotherapy and chemotherapy on prognosis of patients undergoing radical surgery for pancreatic cancer. Methods: Patients with pancreatic cancer who underwent radical surgery from 2010 to 2015 were selected from the SEER database and analyzed by COX proportional risk model, χ2 and Kaplan-Meier. Result: Age is an independent factor affecting postoperative pancreatic cancer patients, and the prognosis of young and middle-aged patients is better than elderly patients, but whether in the elderly group or the middle-aged group, radiotherapy and chemotherapy can improve the prognosis of patients with poor clinical stage and TNM stage. However, chemotherapy and radiotherapy may be detrimental to the prognosis of patients with better differentiation, clinical stage and TNM stage. Conclusion: For patients with poor clinical stage and TNM stage, radiotherapy and chemotherapy can significantly improve their prognosis and prolong their survival cycle.
Keywords:Pancreatic Cancer, Radical Surgery, Prognosis, Radiotherapy and Chemotherapy
苏媛媛,路 宁,李 茜,温 华,张晓庆,马培晗,张明鑫. 放化疗对行胰腺癌根治手术患者预后的影响——基于SEER数据库分析Effects of Radiotherapy and Chemotherapy on Postoperative Prognosis of Patients Undergoing Radical Surgery for Pancreatic Cancer—Based on SEER Database Analysis[J]. 临床医学进展, 2022, 12(10): 9540-9550. https://doi.org/10.12677/ACM.2022.12101380
参考文献ReferencesBray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
<br>https://doi.org/10.3322/caac.21492Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. <br>https://doi.org/10.3322/caac.21654Badiyan, S.N., Molitoris, J.K., Chuong, M.D., et al. (2017) The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surgical Oncology Clinics of North America, 26, 431-453.
<br>https://doi.org/10.1016/j.soc.2017.01.012Maxwell, J.E. and Katz, M.H.G. (2021) Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why? Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract, 25, 843-848. <br>https://doi.org/10.1007/s11605-020-04838-6Manrai, M., Tilak, T., Dawra, S., et al. (2021) Current and Emerging Therapeutic Strategies in Pancreatic Cancer: Challenges and Opportunities. World Journal of Gastroenterology, 27, 6572-6589.
<br>https://doi.org/10.3748/wjg.v27.i39.6572Oettle, H., Neuhaus, P., Hochhaus, A., et al. (2013) Adjuvant Chemotherapy with Gemcitabine and Long-Term Outcomes among Patients with Resected Pancreatic Cancer: The CONKO-001 Randomized Trial. JAMA, 310, 1473-1481.
<br>https://doi.org/10.1001/jama.2013.279201Jin, Z., Hartgers, M.L., Sanhueza, C.T., et al. (2018) Prognostic Factors and Benefits of Adjuvant Therapy after Pancreatoduodenectomy for Ampullary Adenocarcinoma: Mayo Clinic Experience. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44, 677-683. <br>https://doi.org/10.1016/j.ejso.2018.02.008Khawaja, M.R., Kleyman, S., Yu, Z., et al. (2017) Adjuvant Gemcitabine and Gemcitabine-Based Chemoradiotherapy versus Gemcitabine Alone after Pancreatic Cancer Resection: The Indiana University Experience. American Journal of Clinical Oncology, 40, 42-46. <br>https://doi.org/10.1097/COC.0000000000000115Miccio, J.A., Talcott, W.J., Patel, T., et al. (2021) Margin Negative Resection and Pathologic Downstaging with Multiagent Chemotherapy with or without Radiotherapy in Patients with Localized Pancreas Cancer: A National Cancer Database Analysis. Clinical and Transla-tional Radiation Oncology, 27, 15-23.
<br>https://doi.org/10.1016/j.ctro.2020.12.003Van Laethem, J.L., Hammel, P., Mornex, F., et al. (2010) Adjuvant Gemcitabine Alone versus Gemcitabine-Based Chemoradiotherapy after Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD- 9203/GERCOR Phase II Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 4450-4456. <br>https://doi.org/10.1200/JCO.2010.30.3446Neoptolemos, J.P., Stocken, D.D., Friess, H., et al. (2004) A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. The New England Journal of Medicine, 350, 1200-1210.
<br>https://doi.org/10.1056/NEJMoa032295Rutter, C.E., Park, H.S., Corso, C.D., et al. (2015) Addition of Radi-otherapy to Adjuvant Chemotherapy Is Associated with Improved Overall Survival in Resected Pancreatic Adenocarci-noma: An Analysis of the National Cancer Data Base. Cancer, 121, 4141-4149. <br>https://doi.org/10.1002/cncr.29652Hsieh, M.C., Chang, W.W., Yu, H.H., et al. (2018) Adjuvant Radiothera-py and Chemotherapy Improve Survival in Patients with Pancreatic Adenocarcinoma Receiving Surgery: Adjuvant Chemotherapy Alone Is Insufficient in the Era of Intensity Modulation Radiation Therapy. Cancer Medicine, 7, 2328-2338. <br>https://doi.org/10.1002/cam4.1479You, M.S., Ryu, J.K., Huh, G., et al. (2020) Comparison of Efficacy between Adjuvant Chemotherapy and Chemoradiation Therapy for Pancreatic Cancer: AJCC Stage-Based Ap-proach. World Journal of Clinical Oncology, 11, 747-760.
<br>https://doi.org/10.5306/wjco.v11.i9.747Schmohl, K.A., Gupta, A., Grünwald, G.K., et al. (2017) Imaging and Targeted Therapy of Pancreatic Ductal Adenocarcinoma Using the Theranostic Sodium Iodide Symporter (NIS) Gene. Oncotarget, 8, 33393-33404.
<br>https://doi.org/10.18632/oncotarget.16499Fang, L.P., Xu, X.Y., Ji, Y., et al. (2018) Factors Influencing Sur-vival of Patients with Pancreatic Adenocarcinoma after Surgical Resection. Chinese Medical Journal, 98, 606-611.Yamamoto, T., Yagi, S., Kinoshita, H., et al. (2015) Long-Term Survival after Resection of Pancreatic Cancer: A Single-Center Retrospective Analysis. World Journal of Gastroenterology, 21, 262-268.
<br>https://doi.org/10.3748/wjg.v21.i1.262Doi, R., Imamura, M., Hosotani, R., et al. (2008) Surgery versus Ra-diochemotherapy for Resectable Locally Invasive Pancreatic Cancer: Final Results of a Randomized Multi-Institutional Trial. Surgery Today, 38, 1021-1028.
<br>https://doi.org/10.1007/s00595-007-3745-8Liu, L., Xu, H., Wang, W., et al. (2015) A Preoperative Serum Signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL Indicates Poor Outcome to Pancreatectomy for Pancreatic Cancer. International Journal of Cancer, 136, 2216-2227.
<br>https://doi.org/10.1002/ijc.29242Smeenk, H.G., Van Eijck, C.H., Hop, W.C., et al. (2007) Long-Term Sur-vival and Metastatic Pattern of Pancreatic and Periampullary Cancer after Adjuvant Chemoradiation or Observation: Long-Term Results of EORTC Trial 40891. Annals of Surgery, 246, 734-740. <br>https://doi.org/10.1097/SLA.0b013e318156eef3Mirkin, K.A., Greenleaf, E.K., Hollenbeak, C.S., et al. (2016) Time to the Initiation of Adjuvant Chemotherapy Does Not Impact Survival in Patients with Resected Pancreatic Cancer. Cancer, 122, 2979-2987.
<br>https://doi.org/10.1002/cncr.30163Khorana, A.A., Mckernin, S.E., Berlin, J., et al. (2019) Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37, 2082-2088. <br>https://doi.org/10.1200/JCO.19.00946Lee, K.H., Chie, E.K., Im, S.A., et al. (2021) Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. Cancer Research and Treatment, 53, 1096-1103. <br>https://doi.org/10.4143/crt.2020.928Yechieli, R.L., Robbins, J.R., Mahan, M., et al. (2017) Stereotactic Body Radiotherapy for Elderly Patients with Medically Inoperable Pancreatic Cancer. American Journal of Clinical Oncology, 40, 22-26.
<br>https://doi.org/10.1097/COC.0000000000000090